Xtant Medical SEC Filings

Xtant Medical Holdings, Inc. director reports updated equity holdings through an amended Form 4. The filing shows the grant of 158,228 shares of common stock in the form of deferred stock units (DSUs) at a price of $0 on 11/15/2025 under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, if the individual continues to serve as a director through that date, and each DSU represents a contingent right to receive one share of common stock. Following this transaction, the reporting person beneficially owns 914,116 shares, which includes 465,570 shares issuable upon settlement of outstanding DSU awards, each subject to service-based vesting. The amendment states that its purpose is to correct the number of shares shown as beneficially held in the ownership column.

Xtant Medical Holdings, Inc. director equity grant reported

A director of Xtant Medical Holdings, Inc. (XTNT) reported receiving 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award under the company’s Amended and Restated 2023 Equity Incentive Plan. The DSUs will vest on November 15, 2026, provided the director remains on the board through that date, and each DSU represents a contingent right to receive one share of common stock, with settlement deferred to a later date under the award terms.

Following this award, the director beneficially owns 7,515,570 shares on a direct basis, which includes 1,520,215 shares issuable upon settlement of DSUs that are subject to continued service-based vesting conditions.

Xtant Medical Holdings (XTNT) reported an insider equity grant to a director dated November 15, 2025. The director received 158,228 deferred stock units (DSUs) of common stock at a stated price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. Following this grant, the director beneficially owned 517,619 shares directly, including 465,570 shares issuable upon settlement of DSUs, and 1,015,272 shares indirectly through The Platinum Legacy Trust. The new DSU award will vest on November 15, 2026 if the director remains on the board, with settlement of the underlying shares deferred under the DSU award agreement.

Xtant Medical Holdings, Inc. reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, as long as the individual continues to serve as a director through that date. Each DSU represents the right to receive one share of common stock, with actual share delivery deferred to a later date under the award agreement.

Xtant Medical Holdings, Inc. (XTNT)November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a reported price of $0 per share. These DSUs will vest on November 15, 2026, provided the individual remains a director through that date. After vesting, the underlying shares will be settled at a later time according to the DSU award agreement. Following this grant, the director beneficially owns 158,228 shares in the form of DSUs under Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.

Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a grant of 158,228 deferred stock units (DSUs) of common stock on November 15, 2025. The DSUs were granted at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, provided the director continues to serve on the board through that date. Each DSU represents the right to receive one share of common stock, with settlement of the vested shares deferred to a later date in line with the DSU award agreement. Following this grant, the reporting person beneficially owns 158,228 shares in the form of DSUs under the plan.

Xtant Medical Holdings, Inc. reported new equity awards for its President and CEO and director on a Form 4. On 11/15/2025, the executive acquired 394,937 shares of common stock at $0, bringing total beneficial ownership to 2,575,274 shares, held directly. These shares are linked to a deferred stock unit award that vests in installments: 98,734 shares on each of November 15, 2026, 2027, and 2028, and 98,735 shares on November 5, 2029, subject to continued employment.

The filing also reports a grant of 789,874 performance stock units (PSUs), representing the maximum of 200% of a 394,937-share target. Each PSU can convert into one share of common stock, vesting in one-third increments based on stock price performance over a three-year period and additional service-based conditions. The executive’s holdings include 1,213,677 shares issuable upon vesting and settlement of restricted stock units and deferred stock units under the company’s 2023 equity incentive plan.

Xtant Medical Holdings (XTNT) reported new equity awards to its Chief Operating Officer on a Form 4. On 11/15/2025, the officer acquired 292,253 shares of common stock at a price of $0 through a deferred stock unit (DSU) award, bringing total beneficial ownership of common stock to 670,866 shares held directly. The DSU grant will vest in four installments: 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 73,064 shares on November 5, 2029, subject to continued employment, with settlement of shares deferred under the award terms.

The filing also reports a grant of 584,506 performance stock units (PSUs) at a price of $0, which represent a contingent right to receive an equal number of common shares. These PSUs can vest in one-third increments based on stock price performance goals over a three-year period and additional service-based conditions, with 584,506 derivative securities beneficially owned following the grant. The footnotes note that existing holdings include shares issuable under prior RSU and DSU awards from the company’s equity incentive plans.

Xtant Medical Holdings reported an equity award to its CFO and Assistant Secretary. On 11/15/2025, the executive received 263,291 deferred stock units (DSUs) at a price of $0, increasing his beneficial ownership of common stock to 851,465 shares held directly.

The DSUs vest in installments of 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 65,825 shares on November 5, 2029, subject to continued employment, with settlement deferred under the award terms. The filing also reports 526,582 performance stock units (PSUs), representing 200% of a 263,291-share target, which can convert into common stock based on stock price performance over a three-year period and additional service-based vesting conditions.